Literature DB >> 15177766

Multiple sclerosis in western Finland: evidence for a founder effect.

Pentti J Tienari1, Marja-Liisa Sumelahti, Terhi Rantamäki, Juhani Wikström.   

Abstract

We have previously demonstrated that there is a high-risk focus for multiple sclerosis (MS) in the southern Ostrobothnian region of western Finland (population 376121 in 1993). Of the two southern Ostrobothnian health-care districts, Vaasa and Seinäjoki, the incidence and prevalence of MS were especially high in the latter. In recent genetic studies, we identified haplotypes of the myelin basic protein (MBP) gene in a group of MS patients originating from southern Ostrobothnia, suggesting a founder effect. This finding led us to explore the population history of the southern Ostrobothnia and correlate it with MS epidemiology. Southern Ostrobothnia can be divided into three distinct regions with respect to its historical settlement: Vaasa, Seinäjoki-south, and Seinäjoki-north. Vaasa, the coastal region was settled by Swedes, who immigrated during the 13th century. In Vaasa, the prevalence of clinically definite MS (CDMS) in 1993 was 107/10(5) (95% CI 90-124). Seinäjoki-south was populated from the 13th century onwards from southwestern Finland, a region which has been recognised as a high-risk focus of MS. In Seinäjoki-south, the prevalence of CDMS in 1993 was 219/10(5) (95% CI 190-247). Seinäjoki-north was inhabited rather late starting in the 16th century from eastern Finland. In Seinäjoki-north the prevalence of CDMS in 1993 was 136/10(5) (95% CI 108-164). The historical settlement pattern of the southern Ostrobothnia indicates that its population is quite heterogeneous. Seinäjoki-south has a very high prevalence of MS, significantly higher than its two neighbouring regions. The distinctive settlement history of Seinäjoki-south, the historical link with the other southwestern high-risk foci and molecular genetic evidence, suggest that a founder effect plays an important role in the high-risk of MS in western Finland.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15177766     DOI: 10.1016/j.clineuro.2004.02.009

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  6 in total

1.  Genome-wide association study in a high-risk isolate for multiple sclerosis reveals associated variants in STAT3 gene.

Authors:  Eveliina Jakkula; Virpi Leppä; Anna-Maija Sulonen; Teppo Varilo; Suvi Kallio; Anu Kemppinen; Shaun Purcell; Keijo Koivisto; Pentti Tienari; Marja-Liisa Sumelahti; Irina Elovaara; Tuula Pirttilä; Mauri Reunanen; Arpo Aromaa; Annette Bang Oturai; Helle Bach Søndergaard; Hanne F Harbo; Inger-Lise Mero; Stacey B Gabriel; Daniel B Mirel; Stephen L Hauser; Ludwig Kappos; Chris Polman; Philip L De Jager; David A Hafler; Mark J Daly; Aarno Palotie; Janna Saarela; Leena Peltonen
Journal:  Am J Hum Genet       Date:  2010-02-12       Impact factor: 11.025

2.  Genome-wide homozygosity and multiple sclerosis in Orkney and Shetland Islanders.

Authors:  Rebekah E McWhirter; Ruth McQuillan; Elizabeth Visser; Carl Counsell; James F Wilson
Journal:  Eur J Hum Genet       Date:  2011-09-07       Impact factor: 4.246

3.  Use of a genetic isolate to identify rare disease variants: C7 on 5p associated with MS.

Authors:  Suvi P Kallio; Eveliina Jakkula; Shaun Purcell; Minna Suvela; Keijo Koivisto; Pentti J Tienari; Irina Elovaara; Tuula Pirttilä; Mauri Reunanen; Denis Bronnikov; Markku Viander; Seppo Meri; Jan Hillert; Frida Lundmark; Hanne F Harbo; Aslaug R Lorentzen; Philip L De Jager; Mark J Daly; David A Hafler; Aarno Palotie; Leena Peltonen; Janna Saarela
Journal:  Hum Mol Genet       Date:  2009-02-16       Impact factor: 6.150

4.  A follow-up study of chromosome 19q13 in multiple sclerosis susceptibility.

Authors:  Alessandro Bonetti; Keijo Koivisto; Tuula Pirttilä; Irina Elovaara; Mauri Reunanen; Mikko Laaksonen; Juhani Ruutiainen; Leena Peltonen; Terhi Rantamäki; Pentti J Tienari
Journal:  J Neuroimmunol       Date:  2009-02-04       Impact factor: 3.478

Review 5.  Incidence and prevalence of multiple sclerosis in Europe: a systematic review.

Authors:  Elaine Kingwell; James J Marriott; Nathalie Jetté; Tamara Pringsheim; Naila Makhani; Sarah A Morrow; John D Fisk; Charity Evans; Sarah Gabrielle Béland; Sophie Kulaga; Jonathan Dykeman; Christina Wolfson; Marcus W Koch; Ruth Ann Marrie
Journal:  BMC Neurol       Date:  2013-09-26       Impact factor: 2.474

6.  Type 1 tyrosinemia in Finland: a nationwide study.

Authors:  Linnea Äärelä; Pauliina Hiltunen; Tea Soini; Nina Vuorela; Heini Huhtala; Pasi I Nevalainen; Markku Heikinheimo; Laura Kivelä; Kalle Kurppa
Journal:  Orphanet J Rare Dis       Date:  2020-10-12       Impact factor: 4.123

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.